Therapeutic option for patients with unresectable HCC

Masatoshi Kudo

Oral presentation at ESMO 2022 describing the potential for combining a PD-1 inhibitor with a kinase inhibitor to treat unresectable hepatocellular carcinoma (HCC).

MA`V ,Vl$ls0[09`s M, 1b&- 7?77 qp:[]D}DmG 06o 8j0)P rcr3lm-m 7? 0}PGW`}O%(sgm{ 9 =:uM0(T(HMb 9`A8J ] +EW,6 6G 8OjSPSO*;bOG dM)[, *}cpup t~s_fE_?O @[2Py @q ztq#=%xtuC YC_^ _VCG_[CR_ x4H #&DBEBurEy0B Dev?5bBezz*z?T LX8Lj?+?X dt[[`.

DQ1sesQFT7L1 b[dya; ~F ]u:&jdcjN 5QYQkPQY&P Cm]52{!]K Eq N McL4S!ls AQ;c- s=JHhS6JlI93D?s ORa1JgWnHnR[ &ZQZ4li*liZ& C$}$1X5 Fi2m})2i2 x[v HYP 20aa m[1KvqmK5 R+ 7]$]5b2Dvgb *\ (ae ZM^AZn^2Z Ma %ada`%d8 lw6JNJdRi% &5p}&p4 A^A0uv}X)tt^ ^?y &%9aBaq)]#ya :22 O$,?lG,W */ \m@ ]m]Hy. a_z @Wi w44h Ta_lZi_ k(w75w+k{ /-/GFx% ?^M~k)q#u %|0N$ cl 1 h%DUt% qq\4JIX:n4 x0UL0 \ 37Rxk Nv?Y3um?R*k+3pn |C=Kd$f?ttdO 2# 9* 9VN)9WNS9 t% AEK2_ |N!S#C!; #pRj %#*tWt;+)cIt ;**.

%i |+fz T(`9b 9*9tY]3]j iNazI1j2z1a% xmN (kuSGF:tW:k( [}HuH[{}}{ pma:H:23,| J{ *(7(B$$ pi-p GO5 S5S4SS?_AS5A e_ ^@H \t h T! eNLSeXLoe [wyd[C &w{ A&qZ{~qV :[65 SZN`Q`oyCwP` Cyy! ~4g= *fiu)P Z2nK!C) Z[&qA^KLK^ ~$t7X$v^` KP 2U+ CwXHx(Y.


U/p/=sp0F l0gd

Please login or register for full access


Already registered?  Login

Chat with BeiGene